Observational studyCalcified tissue international2025
Prevalence of Comorbid Hyperparathyroidism and Its Association with Renal Dysfunction in Asian Patients with X-Linked Hypophosphatemic Rickets/Osteomalacia.
Observational study in Calcified tissue international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03745521 (An International, Multicenter, Prospective, Longitudinal Observational Study for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia), which is not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An International, Multicenter, Prospective, Longitudinal Observational Study for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Secondary and Tertiary Hyperparathyroidism among Patients with X-Linked Hypophosphatemia: A Systematic Review and Meta-analysis.Calcified tissue international · 2025Pooled it
- Continuation of burosumab during pregnancy in a patient with X-linked hypophosphatemia.JCEM case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In patients with X-linked hypophosphatemic rickets/osteomalacia (XLH) in Asia, the current prevalence of hyperparathyroidism and its association with renal dysfunction have not been determined. We used patient data retrospectively collected up to the time of informed consent in the SUNFLOWER study, a long-term observational study, to investigate the current treatment status and prevalence of comorbid hyperparathyroidism and its association with renal dysfunction in patients with XLH in Japan and South Korea. Of 69 patients who met the eligibility criteria, 32 (46.4%) did not have hyperparathyroidism (hereinafter referred to as non-hyperparathyroidism), 33 (47.8%) had secondary hyperparathyroidism, and four (5.8%) had tertiary hyperparathyroidism. Men were more prone to develop secondary and tertiary hyperparathyroidism, use oral phosphate at higher frequencies, and have a higher incidence of Stage ≥ 3 chronic kidney disease and Grade ≥ 3 renal calcification than women. Ongoing treatments for patients with XLH and non-hyperparathyroidism, secondary hyperparathyroidism, and tertiary hyperparathyroidism mainly consisted of active vitamin D (30 [93.8%], 25 [75.8%], and 3 [75.0%], respectively) and oral phosphate (21 [65.6%], 23 [69.7%], and 4 [100.0%], respectively). At informed consent, patients with tertiary hyperparathyroidism had the lowest estimated glomerular filtration rate values. Our study highlights the prevalence of comorbid hyperparathyroidism and its association with renal dysfunction in patients with XLH through a large-scale observational study in Asia.Trial registration: NCT03745521; UMIN000031605.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.